美银证券发表研究报告指出，康龙化成(03759.HK) 2026年上半年收入按年增长17.9%至76亿元人民币，各业务均录得增长，其中实验室服务收入按年增长13.7%，CDMO收入按年增长32.8%，临床开发收入按年增长13.8%，CDMO毛利率提升2.7个百分点，但被实验室及临床服务受压所部分抵销。考虑到CDMO、实验室服务及临床开发业务快速增长，以及全球口服GLP-1业务的能见度，美银证券将...
Source Link美银证券发表研究报告指出，康龙化成(03759.HK) 2026年上半年收入按年增长17.9%至76亿元人民币，各业务均录得增长，其中实验室服务收入按年增长13.7%，CDMO收入按年增长32.8%，临床开发收入按年增长13.8%，CDMO毛利率提升2.7个百分点，但被实验室及临床服务受压所部分抵销。考虑到CDMO、实验室服务及临床开发业务快速增长，以及全球口服GLP-1业务的能见度，美银证券将...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.